KDR and hepatocellular carcinoma: By inhibiting phosphorylation of serine/threonine kinases (such as Raf kinase) and by blocking RTK signaling (such as VEGFR and PDGFR), donafenib shows similar antitumor activity as sorafenib for the advanced HCC patients (27).